SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: GSK's headquarters in London
Infectious disease
GSK Abandons Herpes Vaccine After Disappointing Phase I/II Proof-of-Concept Data
Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes simplex virus vaccine after failing to meet the study’s primary efficacy objective.
September 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
GLP-1
Novo’s Saxenda Effectively, Safely Lowers BMI in Children: NEJM Study
A study published Tuesday in The New England Journal of Medicine showed that children between the ages of six and 12 who took liraglutide for just over a year experienced a significant reduction in body mass index compared to placebo.
September 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in San Diego, California
Diabetes
Lilly Continues Once-Weekly Insulin Rally With Two Phase III Diabetes Readouts
The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for patients with type 1 and 2 diabetes, respectively.
September 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Concept art showing a money icon and human hands
Funding
Bain Raises $3B for Fourth Fund to Back Promising Life Sciences Companies
Tuesday’s round brings Bain Capital Life Sciences’ fundraising total to around $6.7 billion since its founding in 2016. Many of its portfolio companies have resulted in high-value exits recently, including Cerevel Therapeutics, Aiolos Bio and Jnana Therapeutics.
September 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration showing job candidate searching for job opportunity
Job Search Strategy
Career Coach: Why Fall Is Prime Time for Your Biotech Job Hunt
Plus, learn about what to expect in initial interviews and how to time your post-Ph.D. job search for maximum success.
September 11, 2024
 · 
5 min read
 · 
Carina Clingman
Podcast
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on oral weight loss candidate; and more.
September 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Fashionable halftone collage. Concept of wealth, saving, saving and saving money. Money bag with dollar stacks and stacks of coins. Vector illustration of business and finance for web banner, social media banner, marketing material. Vector illustration
Funding
Terns Announces $125M Raise on Heels of Oral GLP-1 Data Drop
Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big names like Lilly, Pfizer and Roche.
September 10, 2024
 · 
1 min read
 · 
Kate Goodwin
Trendy halftone collage of business concept. Money making concept. Trendy modern retro illustration. Vector illustration of business, contract approval, finance, marketing materials. Vector illustration
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol building
BIOSECURE Act
BIOSECURE Act Sails Through House Passage, Lines Up Senate Vote
The U.S. House of Representatives on Monday overwhelmingly passed the bipartisan bill, which targets WuXi AppTec, WuXi Biologics and other Chinese biotech companies as potential national security risks.
September 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS